Atopic Dermatitis | Access & Reimbursement | US | 2022

The treatment landscape for atopic dermatitis (AD) in the United States is undergoing a revolution. Since 2017, six new agents have been approved by the FDA (four of them since the start of 2021), including two systemic JAK inhibitors, two nonsteroidal topical therapies, and two injectable biological drugs. Treatment of patients with mild and moderate AD relies on topical agents, traditionally corticosteroids, as the mainstay of treatment, while patients with moderate to severe AD may be treated with systemic immunosuppressants like azathioprine or cyclosporine. Newer topical agents like Pfizer’s PDE-4 inhibitor Eucrisa (crisaborole) and Incyte’s JAK inhibitor Opzelura (ruxolitinib) are expanding treatment options for mild to moderate AD, while newer options for the treatment of moderate to severe AD include injectable targeted biologics (Sanofi / Regeneron’s Dupixent [dupilumab] and LEO’s Adbry [tralokinumab]) and systemic JAK inhibitors (Pfizer’s Cibinqo [abrocitinib] and AbbVie’s Rinvoq [upadacitinib]). While Dupixent and Eucrisa, both approved in 2017, have established their niches in AD treatment, the views and policies of physicians and payers on more recently approved therapies, which we explore in depth in this report, will influence physician prescribing of and patient access to these newer therapies and ultimately shape both the AD treatment landscape and the AD drug market.


  • What are the current prescribing practices for AD, and how are they impacted by payer policy?
  • What are physicians’ and payers’ initial reactions to Opzelura, Adbry, Cibinqo, and Rinvoq, and how has / will these agents’ availability for AD impact physician prescribing and payer reimbursement?
  • How will dermatologists’ prescribing of established agents by line of therapy shift as these new agents are incorporated into the treatment algorithm?
  • As systemic JAK inhibitors are granted label expansions for AD, to what extent will payers consider using an indication-based formulary approach?
  • What are payer and physician perspectives on promising but likely costly emerging agents such as Dermira’s lebrikizumab and Chugai / Dermira / Maruho’s nemolizumab?


Geography: United States

Primary Research: Survey of 102 U.S. dermatologists. Survey of 31 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs).

Key Drugs Covered: Dupixent, Eucrisa, Cibinqo, Rinvoq, Olumiant, Adbry, Opzelura, lebrikizumab, nemolizumab, topical corticosteroids, topical calcineurin inhibitors.


U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.

Login to access report

launch Related Market Assessment Reports